US$5bn deal for Galapagos
Belgian biotech Galapagos NV has entered into a R&D collaboration with Gilead Sciences. The US drug maker is paying up to US$5bn for Galapagos pipeline and drug discovery platform.
Author Archive for: UM
About Uta Mommert
This author has not written his bio yet.
But we are proud to say that Uta Mommert contributed 42 entries already.
Entries by Uta Mommert
Boehringer snaps up cancer vaccine developer
/in News/by Uta MommertGerman pharma major Boehringer Ingelheim has taken over Swiss cancer immunotherapy player AMAL Therapeutics.
28.5m for microalgae expert Microphyt
/in News/by Uta MommertFrench microalgae specialist Microphyt has raised 28.5m to develop its microalgae portfolio for nutrition and cosmetics.
8m for universal flu vaccine
/in News/by Uta MommertFrench biotech Osivax has raised 8m to fast-track development of its lead flu vaccine candidate and branch out to Belgium.
BioNTech pulls in massive 290m financing
/in News/by Uta MommertIt is one of the largest single private funding rounds a biotech company in Europe has ever pulled off. German biotech BioNTech managed to raise US$325m (290m) in an upsized […]
Biophytis launches 9m Nasdaq IPO
/in News/by Uta MommertBiophytis has priced its IPO on Nasdaq Paris. The company aims to raise up to 10.8m to advance its lead drug candidate under development for the treatment of neuromuscular diseases.
30m for Evotec cancer spin-out
/in News/by Uta MommertGerman biotech group Evotec has once more launched a spin-off: Breakpoint Therapeutics GmbH is focusing on treating cancer patients by targeting DNA damage responses.
Partnership in pursuit of new antibiotics class
/in News/by Uta MommertA new collaboration aims to the urgent fight against antimicrobial resistant bacteria. Lyon-headquartered biotech Nosopharm has teamed up with German drug discovery company Evotec SE to develop a novel antibiotics […]
Drug puts CAR T activity on hold
/in News/by Uta MommertGerman researchers have found a way to curb the activity of CAR T cells, even while keeping their cancer-fighting properties intact.
License deal in oncolytic virotherapies
/in News/by Uta MommertOncovita has been granted the exclusive license to an immuno-oncolytic measles virus platform developed by the Institut Pasteur. Based on the technology, the Paris-based biotech plans to develop cancer therapies.